Výsledky vyhledávání - "Hristina I. Pashova"

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Autor: Pamela N. Munster, Andrew E. Greenstein, Gini F. Fleming, Erkut Borazanci, Manish R. Sharma, Joseph M. Custodio, Iulia Cristina Tudor, Hristina I. Pashova, Stacie Peacock Shepherd, Andreas Grauer, Jasgit C. Sachdev

Publikováno v: Clinical Cancer Research. 28:3214-3224

Purpose: Chemotherapy resistance remains a major problem in many solid tumors, including breast, ovarian, and pancreatic cancer. Glucocorticoids are one potential driver of chemotherapy resistance as they can mediate tumor progression via induction o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca0cd1621b99f8903527ed9bd529099
https://doi.org/10.1158/1078-0432.ccr-21-4363

Zobrazit plný text záznamu

Supplementary Figure from Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Autor: Jasgit C. Sachdev, Andreas Grauer, Stacie Peacock Shepherd, Hristina I. Pashova, Iulia Cristina Tudor, Joseph M. Custodio, Manish R. Sharma, Erkut Borazanci, Gini F. Fleming, Andrew E. Greenstein, Pamela N. Munster

Supplementary Figure from Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2886d37fcff78b247cd03a79281bc5ec
https://doi.org/10.1158/1078-0432.22487951

Zobrazit plný text záznamu

Supplementary Data from Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Supplementary Data from Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61821b20827be2a56ab1e7f411cae314
https://doi.org/10.1158/1078-0432.22487954

Zobrazit plný text záznamu

Data from Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Purpose:Chemotherapy resistance remains a major problem in many solid tumors, including breast, ovarian, and pancreatic cancer. Glucocorticoids are one potential driver of chemotherapy resistance as they can mediate tumor progression via induction of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49570b9f86aa2860793f871384777c84
https://doi.org/10.1158/1078-0432.c.6532622

Zobrazit plný text záznamu

Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer

Autor: Michael J. Morris, Mark David Linch, Simon J. Crabb, Tomasz M. Beer, Elisabeth I. Heath, Michael S. Gordon, Johann S. De Bono, Hristina I Pashova, Iulia Cristina Tudor, Andrew E Greenstein, Grace Mann, Glenn Liu

Publikováno v: Journal of Clinical Oncology. 41:145-145

145 Background: Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease with significant morbidity. Androgen receptor (AR) signaling is a key driver of tumor growth in mCRPC, and AR-targeted therapies are the mainstay for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0d413e19361c9dec5154ef35552200ab
https://doi.org/10.1200/jco.2023.41.6_suppl.145

Zobrazit plný text záznamu

Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer

Autor: Nicoletta Colombo, Toon Van Gorp, Ursula A. Matulonis, Ana Oaknin, Rachel N. Grisham, Gini F. Fleming, Alexander Olawaiye, Hristina I. Pashova, Dorothy D. Nguyen, Domenica Lorusso

Publikováno v: Journal of Clinical Oncology. 40:LBA5503-LBA5503

LBA5503 Background: Cortisol contributes to chemotherapy resistance by suppressing apoptotic pathways that cytotoxic agents utilize. Preclinical and clinical data indicate that glucocorticoid receptor (GR) modulation with relacorilant (RELA) reverses

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ef77d7a6ebd3dc3f8b04d4a730e2f44
https://doi.org/10.1200/jco.2022.40.17_suppl.lba5503

Zobrazit plný text záznamu

A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma

Autor: Erkut Hasan Borazanci, Nathan Bahary, Paul Eliezer Oberstein, Vincent Chung, Roland T. Skeel, E. Gabriela Chiorean, Andrew E Greenstein, Hristina I Pashova, Iulia Cristina Tudor, Grace Mann

Publikováno v: Journal of Clinical Oncology. 40:4140-4140

4140 Background: Pancreatic cancer remains the third-leading cause of cancer-related death in the US. Average overall survival is only one year, and no standard therapies exist beyond second line. Chemotherapy resistance is one reason for the poor ou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0f819c0f539a424882b7cf9bcab4ac2
https://doi.org/10.1200/jco.2022.40.16_suppl.4140

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání